Does the hs-cTnT-gen6 assay provide comparable diagnostic accuracy to the hs-cTnT-gen5 assay in patients presenting with suspected myocardial infarction?
3,346 patients presenting with suspected myocardial infarction to the emergency department in an international, prospective, diagnostic study.
High-sensitivity cardiac troponin T-generation 6 (hs-cTnT-gen6) assay
High-sensitivity cardiac troponin T-generation 5 (hs-cTnT-gen5) assay
Diagnostic accuracy at emergency department presentation (expressed as area under the curve) and proportion of patients with myocardial injurysurrogate
The novel hs-cTnT-gen6 assay demonstrates excellent diagnostic performance comparable to the established gen5 assay for suspected myocardial infarction, while identifying fewer patients with non-ischemic myocardial injury.
BACKGROUND: The new high-sensitivity cardiac troponin (hs-cTn) T-generation (gen) 6 assay has higher analytical sensitivity than the current hs-cTnT-gen5 assay, but its clinical performance is unknown. OBJECTIVES: The authors aimed to assess the clinical performance and use-optimized cutoffs of the hs-cTnT-gen6 assay. METHODS: In this secondary analysis of an international, prospective, diagnostic study with central adjudication, patients presenting with suspected myocardial infarction to the emergency department were enrolled. hs-cTnT-gen6 and hs-cTnT -gen5 were measured at the same time points. The analytical and diagnostic performance of hs-cTnT-gen6 were compared to hs-cTnT-gen5, and assay-specific cutoffs for the European Society of Cardiology 0/1- and 0/2-hour algorithms were derived and internally and externally validated. RESULTS: Among 3,346 patients, myocardial infarction was the final diagnosis in 616 (18.4%). The proportion of patients with concentrations above the upper reference limit and therefore having myocardial injury was lower for hs-cTnT-gen6 (35.9%) than for hs-cTnT-gen5 (43.5%; P 3 hours) or 3 hours) or <18 ng/L together with a 0/2-hour delta of <4 ng/L ruled out 51.1% with a sensitivity of 99.7% (95% CI: 98.1%-99.9%). An hs-cTnT-gen6 concentration ≥112 ng/L or a 0/2-hour delta ≥15 ng/L ruled-in 23.9% with a specificity 92.7% (95% CI: 90.8%-94.2%). Findings were consistent in sensitivity analyses as well as in the external validation cohort. CONCLUSIONS: The novel hs-cTnT-gen6 assay demonstrated excellent and comparable diagnostic performance to the established hs-cTnT-gen5 assay with fewer patients identified as having myocardial injury. Use-optimized, assay-specific cutoffs for the European Society of Cardiology 0/1- and 0/2-hour algorithms provided very high sensitivity and high specificity. (Advantageous Predictors of Acute Coronary Syndromes Evaluation Study APACE; NCT00470587).
“Coronary artery disease continues to place an immense strain on global health systems, particularly in emergency care, where cases of chest pain are among the most challenging presentations to evaluate. Our new test enables clinicians to detect even the smallest elevations in troponin levels – a critical biomarker for heart attack – with high confidence. This ensures that in a situation when every second counts, patients receive the life-saving care they need at the earliest opportunity, and emergency services can prioritise resources to deliver care effectively to those in urgent need.”
Building similarity graph...
Analyzing shared references across papers
Loading...
Luca Koechlin
University Hospital of Basel
Pedro Lopez-Ayala
University Hospital of Basel
Alexander JF. Thurston
British Heart Foundation
Journal of the American College of Cardiology
University of Edinburgh
University of Zurich
University of Basel
Building similarity graph...
Analyzing shared references across papers
Loading...
Koechlin et al. (Sun,) studied this question.
synapsesocial.com/papers/69fa0a68e8f1e618ec62b829 — DOI: https://doi.org/10.1016/j.jacc.2025.12.052